Abstract

Valproic acid (VPA, valproate, Depakote) is a commonly used anti-seizure medication (ASM) in the treatment of epilepsy and a variety of other neurological disorders. While VPA and other ASMs are efficacious for management of seizures, they also increase the risk for adverse pregnancy outcomes, including neural tube defects (NTDs). Thus, the utility of these drugs during pregnancy and in women of childbearing potential presents a continuing public health challenge. Elucidating the underlying genetic or metabolic risk factors for VPA-affected pregnancies may lead to development of non-teratogenic ASMs, novel prevention strategies, or more targeted methods for managing epileptic pregnancies. To address this challenge, we performed unbiased, whole embryo metabolomic screening of E8.5 mouse embryos from two inbred strains with differential susceptibility to VPA-induced NTDs. We identified metabolites of differential abundance between the two strains, both in response to VPA exposure and in the vehicle controls. Notable enriched pathways included lipid metabolism, carnitine metabolism, and several amino acid pathways, especially cysteine and methionine metabolism. There also was increased abundance of ω-oxidation products of VPA in the more NTD-sensitive strain, suggesting differential metabolism of the drug. Finally, we found significantly reduced levels of hypotaurine in the susceptible strain regardless of VPA status. Based on this information, we hypothesized that maternal supplementation with L-carnitine (400 mg/kg), coenzyme A (200 mg/kg), or hypotaurine (350 mg/kg) would reduce VPA-induced NTDs in the sensitive strain and found that administration of hypotaurine prior to VPA exposure significantly reduced the occurrence of NTDs by close to one-third compared to controls. L-carnitine and coenzyme A reduced resorption rates but did not significantly reduce NTD risk in the sensitive strain. These results suggest that genetic variants or environmental exposures influencing embryonic hypotaurine status may be factors in determining risk for adverse pregnancy outcomes when managing the health care needs of pregnant women exposed to VPA or other ASMs.

Highlights

  • Valproic acid (VPA), marketed as Depakene and Depakote among others, is used widely as an anticonvulsant, a mood stabilizer, a prophylactic, and is used in some cases for treatment of schizophrenia (Wlodarczyk et al, 2012)

  • Since discontinuing use during pregnancy may result in adverse outcomes with respect to the mother’s antiseizure treatment, there is a critical need to elucidate the mechanisms of VPA-induced teratogenesis and to understand the underlying genetic or metabolic mechanisms predisposing to susceptibility for adverse pregnancy outcomes

  • It is has been suggested in the literature that ω-oxidation products of VPA are more toxic than its β-oxidation metabolites (Lheureux and Hantson, 2009), this assumption seems primarily based on the observation that carnitine co-supplementation can reduce toxic effects of VPA. β-oxidation of VPA requires attachment of coenzyme A (CoA) by acyl-CoA synthetasemedium chain (ACSM) enzymes to produce valproyl-CoA, which is shuttled into mitochondria via the carnitine transport system (Silva et al, 2008)

Read more

Summary

Introduction

Valproic acid (VPA), marketed as Depakene and Depakote among others, is used widely as an anticonvulsant, a mood stabilizer, a prophylactic, and is used in some cases for treatment of schizophrenia (Wlodarczyk et al, 2012). It was first approved for medical use in the United States in 1978 as an anti-seizure medication (ASM) and has proven effective against multiple types of seizures (Scott, 1993; Marson and Sills, 2015). Prenatal VPA exposure has been linked to intellectual disabilities and delayed childhood milestones (Daugaard et al, 2020)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call